Enliven Therapeutics: Springing Into 2026 With Data, But I'm Still Cautious

Enliven Therapeutics jumped on strong ELVN-001 phase 1b CML data, but a rich valuation may cap upside. Click here to read an ...
News Medical

CML survey reveals patient TKI adherence, disease anxiety

Survey results suggest that chronic myeloid leukaemia (CML) patients using tyrosine kinase inhibitor (TKI) therapy have good adherence to treatment but might benefit from counselling regarding their ...
Seeking Alpha

Terns Highlights Additional Positive Phase 1 Clinical Data Supporting TERN-701’s Best-in-Disease Potential in Relapsed/Refractory CML at the 67th ASH Annual Meeting

64% MMR achievement by 24 weeks across all efficacy evaluable patients The ASH presentation will be made available on the Terns Pharmaceuticals website simultaneously with the oral presentation by ...
Hosted on MSN

Living with chronic myeloid leukaemia: Najha’s story

KUALA LUMPUR: For many, chronic myeloid leukaemia (CML) is an unfamiliar term. It is a type of blood cancer that begins in the bone marrow and affects white blood cells. While not as common as other ...
MarketWatch

Terns Highlights Additional Positive Phase 1 Clinical Data Supporting TERN-701's Best-in-Disease Potential in Relapsed/Refractory CML at the 67th ASH Annual Meeting

The MarketWatch News Department was not involved in the creation of this content. 64% MMR achievement by 24 weeks across all efficacy evaluable patients 75% MMR achievement by 24 weeks in efficacy ...